CRH Medical Corp (TSE:CRH) – Investment analysts at Clarus Securities lowered their FY2019 earnings estimates for shares of CRH Medical in a research note issued on Wednesday, March 20th, Zacks Investment Research reports. Clarus Securities analyst N. Atkinson now anticipates that the company will post earnings of $0.01 per share for the year, down from their prior estimate of $0.09. Clarus Securities currently has a “Buy” rating on the stock. Clarus Securities also issued estimates for CRH Medical’s FY2020 earnings at $0.09 EPS.
Other equities research analysts have also issued research reports about the stock. TD Securities dropped their price objective on shares of CRH Medical from C$6.50 to C$5.50 and set a “buy” rating on the stock in a research note on Wednesday, January 9th. Acumen Capital dropped their price objective on shares of CRH Medical from C$6.25 to C$6.00 in a research note on Friday, March 15th.
CRH Medical (TSE:CRH) last announced its quarterly earnings results on Wednesday, March 13th. The company reported C$0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$0.03. The company had revenue of C$42.33 million for the quarter, compared to analysts’ expectations of C$41.45 million.
CRH Medical Company Profile
CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.
Recommended Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.